Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, and OhioHealth, a nationally recognized not-for-profit, charitable, integrated health system, today announced a definitive agreement for Quest to acquire select assets of OhioHealth's outreach laboratory services business.

China's respiratory testing market shows significant growth potential, driven by increasing demand, technological advancements, supportive policies, and a growing market size.

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that effective today it has acquired Fluent BioSciences, developer of an emerging and highly differentiated single-cell technology.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received the CE Mark for its Accu-Chek SmartGuide® continuous glucose monitoring (CGM) solution. This significant milestone paves the way for the solution to be made available to people living with type 1 and type 2 diabetes over the age of 18 on flexible insulin therapy.

With the improvement of Chinese manufacturing industry's contribution to the global economy in recent years, more and more international brands, such as Roche, Abbott, Siemens, Beckman, tend to establish the production bases and carry out production in China, to achieve the localization of imported brands. The four giants "Roche, Abbott, Siemens, Beckman" started the localization layout as early as 1985 in China.

Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases.

UK's competition regulator said on Monday it has cleared U.S. medical equipment maker Thermo Fisher Scientific's (TMO.N), opens new tab $3.1 billion deal to buy Swedish biotech firm Olink Holding AB (OLK.O), opens new tab.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

On June 13, 2024, Mindray and Inpeco have officially signed a strategic cooperation agreement at Mindray's headquarters in Shenzhen, China, marking a new era of innovation and collaboration in the in vitro diagnostics industry. This collaboration is founded on the companies’ mutual excellence in their respective fields, as well as their shared values and vision for the future.

Gene Solutions announced Monday that it will partner with the National Cancer Society of Malaysia (NCSM) to expand awareness and enable access to multi-cancer early detection (MCED) testing.

Illumina said on Wednesday that it has signed a research collaboration agreement with the National Cancer Center Singapore (NCCS) to investigate the genomics of a rare cancer in Asians.

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a definitive agreement with OMERS to acquire LifeLabs, a trusted provider of community laboratory tests for millions of Canadians, for a value of approximately CAN $1.35 billion (approximately USD $985 million), including net debt.

In 2019-2020, the industry consolidation has driven the "chain reaction" of IVD industry and becomes a mainstream.

Taiwanese cancer genomics firm ACT Genomics (ACTG) and Japanese clinical testing service provider LSI Medience said Monday that they have signed a memorandum of understanding to advance personalized medicine in Japan.

Roche subsidiary Foundation Medicine said Monday that the US Food and Drug Administration has approved its liquid biopsy test, FoundationOne Liquid CDx, as a companion diagnostic to identify advanced BRCA-mutated prostate cancer patients who are eligible for treatment with Janssen's Akeega (niraparib and abiraterone acetate).